Accepted: 22 July 2020
First Online: 14 September 2020
: No writing assistance or financial support was used in the preparation of this article. C.F.D. has received consultancy and/or lecture fees from companies with an interest in developing and marketing incretin-based therapies for treatment of type 2 diabetes mellitus (Boehringer Ingelheim, Lilly, Merck/MSD and Novo Nordisk). C.F.D.’s spouse is employed by, and holds stock in, Merck/MSD.